SCHEMBL417748

SCHEMBL417748

CCC[C@H](C)[C@@H](O)C(F)(F)C(=O)N[C@@H](C)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CTDSP1 Q9GZU7 1/20 0.45
CASR P41180 1/20 0.44
MME P08473 2/20 0.43
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.42
CTSK P43235 3/20 0.41
HSD17B10 Q99714 1/20 0.41
APAF1 O14727 1/20 0.41
EPHX2 P34913 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13318748 1.00 POLB (0.49) POLBMEN1KMT2ACTDSP1CASR
SCHEMBL417565 0.86 POLB (0.46) POLBMEN1KMT2ACTDSP1CASR
SCHEMBL464153 0.81 CTSK (0.54) POLBMEN1KMT2ACTSK
SCHEMBL5219016 0.75 MEN1 (0.58) POLBMEN1KMT2ACTDSP1HDAC3
SCHEMBL14040888 0.75 MEN1 (0.58) POLBMEN1KMT2ACTDSP1HDAC3
SCHEMBL22499610 0.75 MEN1 (0.58) POLBMEN1KMT2ACTDSP1HDAC3
SCHEMBL29103954 0.74 MEN1 (0.56) POLBMEN1KMT2ACTDSP1HDAC3
SCHEMBL11525977 0.72 MEN1 (0.59) POLBMEN1KMT2ACTDSP1HDAC3
SCHEMBL416777 0.72 EPHX1 (0.33)
SCHEMBL19954260 0.71 RIPK1 (0.68) POLBMEN1KMT2ACTDSP1CASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-02 US disclosed
US-8529882-B2 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-10 US disclosed
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 US disclosed
US-20120064034-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PREP, PEPD POLB 2945/4885MEN1 3086/4885KMT2A 3611/4885
US-20120064034-A1 Peptidomimetic protease inhibitors CTSC, PREP, PEPD POLB 2945/4885MEN1 3086/4885KMT2A 3611/4885
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PEPD, PREP POLB 2212/4885MEN1 3270/4885KMT2A 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.